Search results for ' EDELWEISS DR'

Future Gaming tops electoral bonds list with Rs 1368 cr; who are the others?

Future Gaming tops electoral bonds list with Rs 1368 cr; who are the others?

Rediff.com14 Mar 2024

These are the top buyers of the scrapped electoral bonds, the data for which was released by the Election Commission on Thursday.

Electoral bonds: Congress flags mismatch in donor, recipient files

Electoral bonds: Congress flags mismatch in donor, recipient files

Rediff.com15 Mar 2024

It also asked why the data shared pertained to a period from April 2019 even though the scheme for anonymous political funding was introduced in 2017.

EC reveals electoral bond donors, but not who gave which party

EC reveals electoral bond donors, but not who gave which party

Rediff.com15 Mar 2024

From steel tycoon Lakshmi Mittal to billionaire Sunil Bharti Mittal's Airtel, Anil Agarwal's Vedanta, ITC, Mahindra and Mahindra, and a lesser-known Future Gaming and Hotel Services were among the prominent buyers of the now-scrapped electoral bonds for making political donations.

Electoral bonds: Who is lottery king Santiago Martin?

Electoral bonds: Who is lottery king Santiago Martin?

Rediff.com15 Mar 2024

Future Gaming and Hotel Services whose director is the lottery magnate Santiago Martin is the top purchaser of electoral bonds having purchased bonds worth Rs 1,368, according to data uploaded by the Election Commission of India on its website on Thursday.

Ask MF Guru: 'Where should I invest Rs 15k in SIPs?'

Ask MF Guru: 'Where should I invest Rs 15k in SIPs?'

Rediff.com4 Oct 2022

Nikunj Saraf, Vice President Choice Wealth, answers your queries.

J&J's loss may be good news for Indian pharmas

J&J's loss may be good news for Indian pharmas

Rediff.com1 Nov 2018

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

Pharma stocks make a comeback as Covid cases surge

Pharma stocks make a comeback as Covid cases surge

Rediff.com20 Apr 2021

However, experts caution that investors should not expect the big returns they got from the sector between March and September 2020.

DRL, 1st Indian company to supply generic drugs to China's state hospitals

DRL, 1st Indian company to supply generic drugs to China's state hospitals

Rediff.com27 Sep 2019

The drug that it would supply is called Olanzapine, used to treat schizophrenia and bipolar disorder.

'MF Guru, I know I messed a bit'

'MF Guru, I know I messed a bit'

Rediff.com4 Nov 2022

Omkeshwar Singh, Head, Rank MF, a mutual fund investment platform, answers your queries.

Cyclical stocks to lead India Inc's earnings growth in fourth quarter

Cyclical stocks to lead India Inc's earnings growth in fourth quarter

Rediff.com16 Apr 2021

The earnings are, however, expected to be down around 2 per cent on a sequential basis due to pent-up demand getting exhausted and the adverse impact of rising metals and energy prices on consumer goods and manufacturing companies.

Why IIM-Lucknow grads are celebrating!

Why IIM-Lucknow grads are celebrating!

Rediff.com5 Feb 2019

147 domestic and international recruiters -- including Ola, Amazon, Flipkart and Xiaomi -- hired all 460 graduates.

Time to buy IT and pharma stocks

Time to buy IT and pharma stocks

Rediff.com27 May 2014

IT sector's trading multiples hit post-Lehman lows, providing good entry points.

Labs bet on Covid tests for next growth phase

Labs bet on Covid tests for next growth phase

Rediff.com14 Sep 2020

The bouquet of Covid-19 tests that most diagnostic labs are offering include antibody tests (blood tests), rapid antigen tests (point of care tests that detect the presence of an antigen from a nasal or throat swab in case of SARS-CoV-2), and reverse transcription-polymerase chain reaction (RT-PCR) tests.

ASK AJIT: Will these shares make me rich?

ASK AJIT: Will these shares make me rich?

Rediff.com30 Dec 2021

Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.

Rosier year-end seen for Indian pharma, thanks to faster US approvals

Rosier year-end seen for Indian pharma, thanks to faster US approvals

Rediff.com12 Oct 2015

Rosier year-end seen for Indian pharma thanks to faster US approvals.

Stocks You Must AVOID or EXIT

Stocks You Must AVOID or EXIT

Rediff.com26 Apr 2022

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

ASK AJIT: Stocks To Buy, Sell, Hold

ASK AJIT: Stocks To Buy, Sell, Hold

Rediff.com24 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

Strong US growth to boost pharm cos' fortune in FY14

Strong US growth to boost pharm cos' fortune in FY14

Rediff.com12 Jun 2013

Revival in domestic business should also help overall revenue growth.

Ask Ajit: 'Bought shares at peak; please advice'

Ask Ajit: 'Bought shares at peak; please advice'

Rediff.com30 Mar 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Time to Trump up on large cap stocks

Time to Trump up on large cap stocks

Rediff.com11 Nov 2016

Experts say the stock market correction in recent times increases the risk-reward in favour of large-cap stocks.

Nifty tops 8,500 to end at highest close since August 2015

Nifty tops 8,500 to end at highest close since August 2015

Rediff.com12 Jul 2016

ICICI Bank was the top Sensex gainer after S&P Global Ratings affirmed its 'BBB-' long-term issue ratings on the senior unsecured bonds.

ASK MF GURU: MFs you must buy, hold or exit

ASK MF GURU: MFs you must buy, hold or exit

Rediff.com16 Sep 2021

Omkeshwar Singh, head, Rank MF, a mutual fund investment platform, answers your queries.

Ask MF Guru: 'Can I achieve Rs 1 crore target in 10 years?'

Ask MF Guru: 'Can I achieve Rs 1 crore target in 10 years?'

Rediff.com19 Mar 2021

Omkeshwar Singh, Head, Rank MF, a mutual fund investment platform, answers your queries.

Local banks top IPO league table in 2015

Local banks top IPO league table in 2015

Rediff.com4 Jan 2016

Indian companies are now more confident about the execution skills of local banks.

Do you own these stocks? EXIT them NOW

Do you own these stocks? EXIT them NOW

Rediff.com22 Sep 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Is this a good opportunity to invest in stocks?

Is this a good opportunity to invest in stocks?

Rediff.com25 Aug 2015

The turmoil on the Street and a continued fall of the rupee may affect growth stocks, pushing equity investors back to the relative safety of defensive counters, or forcing them to flee markets, or both.

Profit boom amid sales gloom

Profit boom amid sales gloom

Rediff.com8 Jul 2013

Brokerages expect Nifty50 firms to post 11.8% growth in net profit in Q1 but sales may decline

Economic recovery: Will India Inc get third time lucky?

Economic recovery: Will India Inc get third time lucky?

Rediff.com6 Jun 2016

This analysis is based on the quarterly earnings for 724 companies.

Mint a fortune from these 10 best performing stocks

Mint a fortune from these 10 best performing stocks

Rediff.com29 Feb 2016

The past decade saw three full cycles of markets moving up and then going into bear phases.

Nifty50 show suggests end of downgrade cycle

Nifty50 show suggests end of downgrade cycle

Rediff.com18 Nov 2013

The sharp fall in the rupee's value against the dollar during the July-September quarter, it turns out, has come as a boon for corporate earnings.

Markets to remain volatile on global cues

Markets to remain volatile on global cues

Rediff.com18 Dec 2014

But experts say downside limited, pockets of opportunities for investors

Friday the 13th hits stocks, rupee once again; gold shines

Friday the 13th hits stocks, rupee once again; gold shines

Rediff.com13 Jun 2014

BSE Mid-cap and BSE Small-cap lost 2.5% and 3.1% after oil prices soared

Long road to full recovery for India Inc

Long road to full recovery for India Inc

Rediff.com2 Jun 2014

Net profit grew 25.4% in Q4 but revenue growth, lower at 8.5%, suggests lack of volume expansion.

Stock advice: Buy, sell, hold or avoid?

Stock advice: Buy, sell, hold or avoid?

Rediff.com22 Aug 2019

Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis